Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170157 · ClinicalTrials.gov registry record · Phase 2
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
A Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT00170157: Completed Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma, sponsored by Mayo Clinic.
NCT00170157 is a Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma that has completed, run by Mayo Clinic. The registered enrollment target is 112 participants, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00170157, a Phase 2 study of Prostate Adenocarcinoma and Prostate Carcinoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
Primary Outcome
PSA progression is defined as a rise in PSA to \>4.0 ng/mL demonstrated twice in measurements taken two weeks apart.
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG Bicalutamide
- DRUG Goserelin Acetate
- DRUG Leuprolide Acetate
- DRUG Flutamide
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2004-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT00170157 record still lists
NCT00170157 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (48% lower).
The record links to 5 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Ipilimumab is the first listed.
NCT00170157 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00170157 about?
NCT00170157 is a clinical study titled "Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some b...
What is the current status of trial NCT00170157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2004-06. Estimated completion is 2013-06.
What conditions does trial NCT00170157 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Stage III Prostate Cancer.
What interventions are being tested in trial NCT00170157?
The interventions under investigation include: Ipilimumab (DRUG), Bicalutamide (DRUG), Goserelin Acetate (DRUG), Leuprolide Acetate (DRUG), Flutamide (DRUG).
Who is sponsoring clinical trial NCT00170157?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00170157 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00170157's enrollment target sits among peer trials
112 37th of 99 higher than 63 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia